Table 3 Pooled prevalence of mental health disorders, respiratory impairment, musculoskeletal impairment, hearing impairment, visual impairment, and neurological impairment, stratified by study characteristics

Overall

43

20.7

41

23.1

27

14.5

33

1.6

9

9.8

9

17.1

Countries income level

 High-income

9

14.9

3

4.3

1

59.1

9

1.3

3

11.1

1

2.5

 Upper middle-income

12

15.3

14

30.6

11

27.4

8

15.9

2

3.1

4

32.5

 Lower middle-income

19

56.1

18

31.3

11

11.0

13

25.6

4

10.7

4

4.7

 Low-income

3

61.2

6

42.0

4

5.0

3

5.9

-

-

-

-

Type of TB

 Drug susceptible

24

33.1

24

21.9

2

2.3

17

12.5

4

11.9

8

20.2

 Drug resistant

7

58.7

7

26.0

20

15.0

6

4.6

3

2.7

-

-

 Drug susceptible and drug resistant (no injectable)

-

-

-

-

1

2.6

3

28.5

1

6.5

-

-

 Drug susceptible and drug resistant (injectable)

4

33.1

6

20.7

3

25.0

5

37.2

-

-

1

2.5

Study design

 Cohort

28

18.1

15

23.2

24

14.5

28

1.5

9

9.8

8

23.0

 Cross-sectional

10

54.5

22

33.3

3

13.6

4

6.8

-

-

1

2.7

 Case control

5

47.9

4

05.0

-

-

1

30.5

-

-

-

-

HIV (%)

 < 1

5

14.7

5

4.9

3

2.7

5

9.0

1

1.1

3

21.2

 1–50

9

51.8

12

31.5

10

12.5

11

8.2

3

3.3

1

38.2

 51–100

3

38.9

6

30.0

3

22.5

12

65.1

.

-

-

-

 Not recorded

26

18.8

18

38.5

11

26.4

16

1.3

5

11.5

5

12.8

Timing of disability diagnosis

 Before TB treatment

9

17.6

1

64.2

-

-

6

8.9

1

75.0

1

36.9

 During TB treatment

6

61.0

35

22.0

22

14.7

11

1.23

4

3.0

6

12.4

 After TB treatment

27

19.3

2

19.8

4

14.1

14

40.9

4

11.1

2

4.0

 Not recorded

1

63.2

3

44.7

1

4.3

2

5.7

-

-

-

-